stockrowMaravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
Follow MRVI
Alert me
Maravai LifeSciences Holdings, Inc. (MRVI) P/B ratio
As of 6 November 2026, Maravai LifeSciences Holdings, Inc. (MRVI) trades at a P/B ratio of 3.3×. Over the past ten years it has ranged from 0.5× (April 2025) to 54.2× (December 2020); the current reading is higher than 67% of that period. That is above the Biotechnology industry median of 2.1× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 1.3× | (3.33%) |
| FY2024 | 1.3× | 15.67% |
| FY2023 | 1.1× | (43.42%) |
| FY2022 | 2.0× | (77.44%) |
| FY2021 | 8.8× | 20.30% |
| FY2020 | 7.3× | (86.01%) |
| FY2019 | 52.4× | 0.00% |
| FY2018 | 52.4× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 3.4× | 29.25% |
| Jun 2026 | 2.6× | 131.33% |
| Mar 2026 | 1.1× | (10.81%) |
| Dec 2025 | 1.3× | 30.92% |
| 24 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| SRPT Sarepta Therapeutics, Inc. compare | 1.2× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 1.8× |
| MESO Mesoblast Limited compare | 1.9× |
| VIR Vir Biotechnology, Inc. compare | 2.3× |
| MRVI Maravai LifeSciences Holdings, Inc. | 3.3× |
| MAZE Maze Therapeutics, Inc. compare | 4.5× |
| TRVI Trevi Therapeutics, Inc. compare | 6.9× |
| REPL Replimune Group, Inc. compare | 11.2× |
| TRAX First Tracks Biotherapeutics, Inc. compare | 11.3× |
| Biotechnology industry median | 2.1× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))